PMC18 MULTI-NATIONAL CHART REVIEW STUDIES IN EUROPE: OPPORTUNITIES AND CHALLENGES  by Payne, KA et al.
A332 13th Euro Abstracts
PMC18
MULTI-NATIONAL CHART REVIEW STUDIES IN EUROPE: 
OPPORTUNITIES AND CHALLENGES
Payne KA1, Wasiak R2, Stein D1, Chancellor J3
1United BioSource Corporation, Dorval, QC, Canada; 2United BioSource Corporation, 
London, UK; 3Chancellor Health Economics Ltd, Beaconsﬁ eld, Buckinghamshire, UK
OBJECTIVES: In support of European pricing and reimbursement submissions, 
country-speciﬁ c health economic evidence is required. In the absence of patient-level 
databases, multi-national, retrospective chart review studies can provide data related 
to real-world patient characteristics, patterns of care, clinical outcomes and the natural 
history of disease. METHODS: A critical review and qualitative analysis of six recent 
multi-national chart review case studies designed to inform health economic questions 
was performed to characterize common research aims, objectives, and design param-
eters, and to delineate main methodological, operational and analytic challenges. 
RESULTS: Design challenges include deﬁ ning an eligibility period sufﬁ ciently long to 
obtain enough cases while accessing patterns of care that are current, sample size 
determination and balancing the need for stable estimates of resource utilization with 
the need to contain study costs, and delineating sampling frame methodology to mini-
mize chart selection bias. Detailed treatment and clinical outcome data must be 
weighed in the context of abstractor burden, and data collection methods should be 
considered separately from data interpretation. a common case report form for multi-
national studies should allow local area treatment variation while maintaining consis-
tency in data collection across health care settings. Operationally, knowledge of 
country-speciﬁ c ethics and privacy protection regulations for retrospective studies is 
paramount as requirements are diverse and impact timelines differently. Successful 
study execution is also dependent on the ability to rapidly identify and recruit clinical 
sites representative of a broad range of clinical practice that also can provide sufﬁ cient 
geographical coverage. CONCLUSIONS: Despite signiﬁ cant challenges, practical, 
efﬁ cient, and scientiﬁ cally sound approaches to the design and conduct of multi-
national chart review studies in support of health economic analyses are possible. 
Main methodological and operational challenges can be identiﬁ ed across studies, thus 
can be anticipated and planned for. 
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THE THRESHOLD PRICING MODEL: NOT JUST ANOTHER COST-
EFFECTIVENESS MODEL
Mladsi D1, Earnshaw S1, Akashi-Ronquest N1, Keith MS2
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BACKGROUND: Threshold analysis as it is typically applied to cost-effectiveness 
models is an extension of sensitivity analysis in which the threshold analysis may be 
used to demonstrate the maximum price given different levels of health outcomes 
resulting in cost-effectiveness. In these instances, the ICER is the primary result of the 
model, and threshold analysis aids interpretation. As a result, the model is restricted 
to the intended target indication, population, and line of therapy, reﬂ ecting key 
development decisions that have already been made. In contrast, a threshold pricing 
model, which is developed early in a drug’s development, is not attempting to evaluate 
the drug’s cost-effectiveness. Instead, it is built to inform the development plan, pricing 
strategy, and go/no-go investment decisions. OBJECTIVES: To outline the differences 
in the underlying mathematical structure, inputs, and outputs of a threshold pricing 
model compared with a traditional cost-effectiveness model, and to demonstrate its 
application. METHODS: We present the algebraic manipulations required to convert 
a decision-analytic model into one used for threshold pricing analysis. Using a hypo-
thetical new pharmaceutical possessing two versions of a product proﬁ le, we demon-
strate application of the threshold pricing model by generating a table of potential 
value-based pricing estimates corresponding to the unique combinations of indication, 
subpopulation, line of therapy, and comparator. We provide graphical depictions of 
the lost value-based pricing opportunity (reﬂ ecting the lost opportunity for the new 
product to address a greater unmet need) of development strategies that are not value-
driven. CONCLUSIONS: a threshold pricing model is a powerful tool for helping to 
construct a value-driven development plan and a value-based pricing strategy. Con-
structed appropriately, threshold pricing models can be used to prioritize among 
possible indications, identify target subpopulations, select the appropriate line of 
therapy, and choose and clarify required performance against comparators.
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THE OPTIMAL NUMBER OF MONTE CARLO SIMULATIONS TO BE 
PERFORMED IN PROBABILISTIC SENSITIVITY ANALYSIS: EMPIRICAL 
EVIDENCE FROM ECONOMIC MODELS CONSTRUCTED FOR 
SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND 
CLINICAL EXCELLENCE
Batty AJ1, Paulden M2
1BresMed Health Solutions, Shefﬁ eld, UK; 2University of Toronto, Toronto, ON, Canada
OBJECTIVES: Probabilistic Sensitivity Analysis (PSA) is a common technique to assess 
uncertainty in economic models, with the majority of economic model publications 
now containing some form of PSA. Historically the number of simulations performed 
has been set at arbitrary levels (e.g. 1,000 simulations), however the aim of this 
research is to rationalise the number of simulations performed, minimizing both 
wasted computational time and the risk of incorrect conclusions being drawn. 
METHODS: The analysis investigates the number of simulations required in order for 
a Cost-Effectiveness Acceptability Curve (CEAC) to remain stable at the periphery. 
Secondary analyses focused on the number of simulations required to give reliable 
estimates of the mean values in these (non-linear) models. In the UK the National 
Institute for Health and Clinical Excellence (NICE) require manufacturers to submit 
PSA as part of the Single Technology Appraisal (STA) process. Models from different 
contract research agencies that have been constructed in Microsoft Excel, for submis-
sion to NICE, were then used to generate 50,000 simulations per model. This data 
was retrospectively analyzed to determine the number of simulations required such 
that a cost-effectiveness acceptability curve would remain stable at the periphery (5th 
and 95th percentiles). Secondary analyses focused on the number of simulations 
required to give reliable estimates of the mean values in these (non-linear) models. 
RESULTS: Preliminary analyses suggest that conventional numbers of simulations are 
sufﬁ cient to estimate the CEAC at low levels of precision at the 5% and 95% limits and 
generate the mean value. However this is not the case if high levels of precision are 
required. CONCLUSIONS: Research in to the optimum number of Monte Carlo 
Simulations allows analysts to ground the number performed in empirical data, and 
suggests that accuracy can be achieved without spurious precision, wasted computing 
time, or worse, unreliable/unstable conclusions.
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USING GROWTH IN THE COST-EFFECTIVENESS THRESHOLD TO 
INFORM THE DIFFERENTIAL BETWEEN THE DISCOUNT RATES ON 
COSTS AND HEALTH EFFECTS: REASON TO BE CAUTIOUS?
O’Mahony J
Erasmus University Medical Center, Rotterdam, The Netherlands
BACKGROUND: Differential discounting of the costs and effects of health care 
interventions has been extensively debated. Proponents argue that a rising valuation 
of health as incomes grow justiﬁ es discounting health effects at a lower rate than costs. 
However, despite that fact that the impact of differential discounting is highly sensitive 
to the difference between the two rates, little attention has been paid what the appro-
priate differential should be. The existing justiﬁ cation for the differential rests the 
income and health elasticities of utility and income and health growth rates, all of 
which are uncertain: estimates of the appropriate differential are speculative at best. 
The discount differentials recommended by cost-effectiveness analysis advisory bodies 
vary, being 1.5 percentage points in Belgium, 2.5 in the The Netherlands and 4.5 in 
the UK prior to 2004. What has not been widely recognised is that the differential 
should approximate the annual rate of growth in the cost-effectiveness threshold: this 
has been shown in a simple model published in the literature in which decision makers 
use a cost-effectiveness threshold in their reimbursement decision rule. ANALYSIS: 
This link to threshold growth provides a more immediate alternative by which empiri-
cally determine the appropriate differential compared to the current estimates. While 
cost-effectiveness thresholds are often not made explicit, there is no strong evidence 
that they have risen in recent years. Indeed, there are reasons to expect thresholds to 
remain constant or even decline, even if income growth is positive. CONCLUSION: 
This consideration of the plausible discounting differential complements current theo-
retical debate over differential discounting. Growth in cost-effectiveness thresholds 
provides an alternative basis for justifying the discount differential. Existing evidence 
and expectations of threshold growth leads to conservative estimates of the discount-
ing differential of at or near zero.
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REVENUE OPTIMIZATION MODEL TO OPTIMISE POSITION AND 
INDICATION OF NEW LAUNCHES
Mukku S, McConkey D
Double Helix Consulting Group, London, UK
OBJECTIVES: To assess the impact on revenues from a new drug in different indica-
tions and at different positions within a treatment pathway. METHODS: The model 
was developed by price modeling experts at Double Helix Consulting using a logical 
ﬂ ow developed over years. The model is tested by internal and external experts with 
different products. RESULTS: Drugs that reach to market very rarely are released in 
only a single indication, especially in chronic disease areas where there may be several 
different illnesses with a related etiology but different presentation. This is exempliﬁ ed 
in the ﬁ eld of immunology and rheumatology, where several different drugs with a 
similar MOA are being used to treat many conditions that are pathophysiologically 
related. To explore the impact that multiple indications or use in different lines has 
or will have on the pricing of a new therapeutic agent, Double Helix Consulting gener-
ated a revenue optimization model that can be used to establish the most likely price 
point for a new drug given several different scenarios. This model will help in optimiz-
ing the best position and or indication for long term revenues from the drug. The 
model uses EPI data, prevalence, incidence, number of competitors, prices of compara-
tors, line of treatment and other inputs. The outputs include NPV over a chosen period 
of time that can be sorted by line of treatment and indication. CONCLUSIONS: While 
it is desirable for a drug to be indicated in the largest patient pool possible, such 
actions can have serious negative consequences for the price at which payers are 
willing to pay for the treatment. a larger patient pool makes the burden on the health 
care provider signiﬁ cant if the drug is too expensive, and as a result can lead to sig-
niﬁ cant price erosion or HTA rejection.
